Skip to main content
. 2013 Oct;4(5):320–334. doi: 10.1177/2040620713490316

Table 5.

Clinical trials with ECP in acute GVHD.

Study ECP regimen Number of patients Skin GI Liver OS (%)
Greinix et al. [1998] Twice every 2 weeks for 3 months, then twice monthly 6 OR=100% OR=100% 100
CR=67% CR=100%
Greinix et al. [2000] Twice every 1–2 weeks to response then twice every 2–4 weeks 21 OR=81% OR=None OR=67% 57
CR=62% CR=67%
Salvaneschi et al. [2001]* Thrice weekly to response then twice every 2 weeks for 3 months 9 OR=89% OR=60% OR=20% 67
CR=67% CR=60% CR=20%
Messina et al. [2003]* Twice weekly for 1 month, then twice every 2 weeks for 2 months, then twice monthly for 3 months 33 OR=82% OR=75% OR=60% 58
CR=76% CR=75% CR=60%
Perotti et al. [2010]* Twice–thrice weekly to response then twice weekly for 1 week then twice every 2 weeks then twice monthly 50 OR=83% OR=73% OR=67% 44
Greinix et al. [2006] Twice weekly to response then twice every 2–4 weeks 59 CR=82% CR=60% CR=61% 47
Perfetti et al. [2008] Twice weekly for 1 months, then twice every 2 weeks for 2 months, then twice monthly until CR or stabilization 23 CR=66% CR=40% CR=27% 48

CR, complete response; ECP, extracorporeal photopheresis; GI, gastrointestinal; GVHD, graft-versus-host disease; OR, overall response (complete + partial response); OS, overall survival.

*

Study involving pediatric patients.